We are live on ! Find out more
TBRA

Tobira Therapeutics, Inc. Common Stock
TBRA

Delisted

TBRA was delisted on the 31st of October, 2016.

47 hedge funds and large institutions have $5.9M invested in Tobira Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more call options, than puts

Call options by funds: $4K | Put options by funds: $4K

7% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 14

4% less funds holding

Funds holding: 4947 (-2)

15% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 13

91% less capital invested

Capital invested by funds: $64.6M → $5.9M (-$58.7M)

Holders
47
Holders Change
-2
Holders Change %
-4.08%
% of All Funds
1.36%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
13
Reduced
14
Closed
13
Calls
$4K
Puts
$4K
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
51
Millennium Management
New York
-$227K -3,718 Closed
DCM
52
DAFNA Capital Management
California
-$204K -3,333 Closed
DAM
53
Deltec Asset Management
New York
-$181K -2,956 Closed
Bank of America
54
Bank of America
North Carolina
-$13.9K -704 -98%
Deutsche Bank
55
Deutsche Bank
Germany
-$6.6K -334 -95%
Bank of Montreal
56
Bank of Montreal
Ontario, Canada
-$20K -333 Closed
BJ
57
BlackRock Japan
Japan
-$15K -246 Closed
VFA
58
Virtus Fund Advisers
Connecticut
-$9K -146 Closed

TBRA Hedge Fund Activity: Q3 2014 in Review

47 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Tobira Therapeutics, Inc. Common Stock (TBRA) for Q3 2014, worth a combined $5.9M — down 91% from $64.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of TBRA and 11 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 13 added.

The largest buyer was Sabby Management, adding an estimated $1.93M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $15.4M sold.

  • 47 institutional investors held Tobira Therapeutics, Inc. Common Stock (TBRA) as of Q3 2014, down from 49 in Q2 2014.
  • Funds reported $5.9M of Tobira Therapeutics, Inc. Common Stock stock for Q3 2014, down 91% quarter-over-quarter.
  • 11 funds opened new Tobira Therapeutics, Inc. Common Stock positions in Q3 2014 and 13 closed out, a net change of -2 holders.
  • The largest Tobira Therapeutics, Inc. Common Stock buyer in Q3 2014 was Sabby Management, an estimated $1.93M added.
  • The largest Tobira Therapeutics, Inc. Common Stock seller in Q3 2014 was Gilder Gagnon Howe & Co, an estimated $15.4M sold.

Based on aggregated 13F filings for Q3 2014.